>> it is a great product. sold $800 million, some of the reports i have read, suggest in 2013, $1.5 billion. quickly took market share, due to many frequent, less frequent injection cycles. our product is in phase two, one has to always be cautious. if it pans out, what we have seen in early limited studies, our drug maybe lasts for three to four months, and what an advantage it would be for the patients to go, from say, ten injections per year, with lucentis to, say, seven or six for ilea, to potentially, three, or four, if our technology, we have on license from switzerland, all works out. >> that is injections into the the eye.